Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. - Wikidata - awgldk - TriplyDB

Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.

Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.

http://www.wikidata.org/entity/Q36330568

about

Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis Cystic fibrosis chronic rhinosinusitis: a comprehensive review Cystic fibrosis therapeutics: the road ahead Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher.Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies.High-Dose Ibuprofen in Cystic Fibrosis.Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis Translating scientific advances to improved outcomes for children with sickle cell disease: a timely opportunity.Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis.Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.Anti-inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis Multimonth controlled small molecule release from biodegradable thin films.The role of inhaled corticosteroids in the management of cystic fibrosis.Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis Characterizing aggressiveness and predicting future progression of CF lung disease.State of progress in treating cystic fibrosis respiratory disease.Is adolescents' religious coping with cystic fibrosis associated with the rate of decline in pulmonary function?-A preliminary study.Impact of MIF gene promoter polymorphism on F508del cystic fibrosis patients Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation GBA2-encoded β-glucosidase activity is involved in the inflammatory response to Pseudomonas aeruginosa.The effects of an intensive behavior and nutrition intervention compared to standard of care on weight outcomes in CF Potential of anti-inflammatory treatment for cystic fibrosis lung disease.Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.New use for an old drug: COX-independent anti-inflammatory effects of sulindac in models of cystic fibrosis.Cyclic AMP: master regulator of innate immune cell function.Update in cystic fibrosis 2007.Antibiotic and anti-inflammatory therapies for cystic fibrosis.Highlights of a workshop to discuss targeting inflammation in cystic fibrosis Increased adherence to CFF practice guidelines for pulmonary medications correlates with improved FEV1.An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease.Assessment and monitoring of cystic fibrosis lung disease in infants and young children.Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life.Targeting airway inflammation in cystic fibrosis in children: past, present, and future.

P2860

Q24185912-0A80FDC3-75EC-4198-A7E3-41A66AE5C2CA Q24201968-9C0E0F8A-4413-41F9-B52D-6FB38FDA130B Q24243302-0CB76F36-1F0D-4D7A-8A84-3CF1A718912B Q27003313-26836A5E-EB64-44A7-A889-75B1AFBF5B11 Q27022401-22B8C906-2BD4-46F7-BD15-8E22CEC05EBA Q28073063-A5C07BBE-0EDE-488F-955A-432CFBECEC9F Q28388812-643A78D9-3F29-4FEA-97B5-9221679CC308 Q30238814-C1D57CCD-D2FC-4E68-BA8E-C90769CBD61D Q33522442-B24904D5-3185-4EFA-A747-343144057CBA Q33678000-D5677F6A-EF0B-4CEE-BE56-61FECFF74C91 Q33811280-43B4F98C-1A07-4E99-B0C7-2D24454AB87C Q33871218-6BFBDCE0-5586-4C52-BD5B-831D40A8C7D0 Q33942782-F0EF3DCC-C254-4BC1-B685-774B835C3A91 Q33957181-B27F7539-A502-42CD-9658-A64976B7B48E Q33985943-5078A7C9-1B20-40AF-9E06-66A7F3EF2590 Q34082780-01C1EBB1-BA4C-4440-9D6B-421035B16C9E Q34131911-BA599348-F7C4-4340-B515-EB6E3A6DAFBF Q34179764-C1022D95-6752-45ED-BA46-581A33D12E72 Q34204139-6C1ADF52-2D86-4B0F-BAAB-27B9B17D1D98 Q34375926-9A9370D1-55DC-42B6-85B5-36419B65E364 Q34646358-A4EE34A1-FF9C-4A66-AC1E-EC93E5C8BA24 Q34689530-73797489-C47B-434F-8EE3-16394A601CE3 Q35073075-D3797449-8EF8-4FEE-A7E8-452C844E448C Q35228672-5107259B-2FB5-42F1-A88F-5AE8EF244E66 Q35541500-FE35225C-FEC5-4116-8C22-B169D38D2C19 Q35557381-F8F2BE2E-2274-41A2-A8A0-B709CA82B7C0 Q35801062-02751C7F-D5F6-431F-B050-71794CB8C12A Q36584924-41867248-58C0-4711-AF7A-102D1B5AC2B1 Q36609344-578EEF6C-764C-488E-8067-92F973012E38 Q36903409-B631B3FB-454E-4BC3-8C05-1165EAB83BD8 Q37103511-00C0E5F5-77F1-4335-BE48-CFAD7FA28765 Q37156059-F3D2B4ED-4E2C-4B29-A8F0-7BCF8DF3732C Q37201467-A95EDCB7-3EE6-497A-B94F-D4FD5CFB4EC5 Q37330935-D7561EFB-7649-49FF-A799-05F23E69BA18 Q37377680-6EB8EE9F-D439-41A0-966C-3F201D4F34A2 Q37403066-29BC805A-C2C0-4BA8-9189-498923C5F6A3 Q37421287-2AD774F7-D9EE-414D-9367-549FAC6B312C Q37754879-5BBC0C6F-8412-40F1-AD5A-6FCB4BACA42F Q37844338-5645E4D4-B15B-4D7C-850E-6D8A7421636A Q37866284-3D3F17D4-D257-481F-8F0A-935C68E619D7

P2860

Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.

http://www.wikidata.org/entity/Q36330568

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Clinical use of Ibuprofen is a ...... children with cystic fibrosis.

@ast

Clinical use of Ibuprofen is a ...... children with cystic fibrosis.

@en

type

label

Clinical use of Ibuprofen is a ...... children with cystic fibrosis.

@ast

Clinical use of Ibuprofen is a ...... children with cystic fibrosis.

@en

prefLabel

Clinical use of Ibuprofen is a ...... children with cystic fibrosis.

@ast

Clinical use of Ibuprofen is a ...... children with cystic fibrosis.

@en

P1433

Q36330568-12AF60E0-6A9C-4F90-954D-04CC200F486E

P1476

Q36330568-06A9F913-2E3C-4353-80AE-3137352C2FDF

P2093

Q36330568-290FBE0A-812B-4057-B626-2544BC000449

Q36330568-348351F7-3B0E-4D97-96A8-9491954E1016

Q36330568-AD30C554-FA64-4F52-8E45-31F0A69D7458

Q36330568-E7C2FC84-22DD-4A74-8235-33E1D0CDE42A

P2860

Q36330568-0B4460A6-235D-43E0-B37F-ADFEF76EC4B9

Q36330568-0E235E25-0EB3-44E2-8367-4FEB8BCB38EF

Q36330568-1389F2C6-6DE4-4116-B595-EE22B90E33B8

Q36330568-26F9D75E-C984-41D5-A385-B44E05EA35DD

Q36330568-3BBC9703-70A6-4A0A-B842-6836A75E0B2F

Q36330568-54EFCAE0-A005-42A5-87CF-B0EE7B7F980D

Q36330568-60475E33-6377-4C45-83A5-9A47872B4F36

Q36330568-8858B67F-86F7-411C-B72E-50570A66E873

Q36330568-A5B26F08-4419-4C8E-A834-A10EA15BCB2C

Q36330568-B087AE7F-2558-4185-80EE-B2D0FF020936

P304

Q36330568-F6CED1CE-D725-4D20-91C1-4CAFE0C06944

P31

Q36330568-836D2516-59E9-4382-8976-2CD9AF47F6DD

P356

Q36330568-4A97AACD-D218-4ACB-9FD9-9EE04F82FC13

P407

Q36330568-34672C3D-8C4A-4966-B6AD-CF13EAEABA63

P433

Q36330568-FF4F0F5E-2077-4E2E-9BA7-1BECC01F0CB4

P478

Q36330568-793EBBA1-9682-4A99-8CFB-E6DFD52E7D51

P577

Q36330568-D942611E-E0BA-4A09-9B8F-15DAD6BAE4D6

P698

Q36330568-9E11E711-1F2C-431D-892B-471D4EADE884

P921

Q36330568-FAFA1783-39ED-432D-8306-947871BE7070

P932

Q36330568-9CEF47C6-F1A6-4152-B899-B8F254F40B32

P356

RCCM.200702-181OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Clinical use of Ibuprofen is a ...... children with cystic fibrosis.

@en

P2093

Mark D Schluchter

http://www.w3.org/2001/XMLSchema#string

Michael W Konstan

http://www.w3.org/2001/XMLSchema#string

Pamela B Davis

http://www.w3.org/2001/XMLSchema#string

Wei Xue

http://www.w3.org/2001/XMLSchema#string

P2860

High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report

Changes in the normal maximal expiratory flow-volume curve with growth and aging.

Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis.

Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis.

Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.

Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen.

The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes.

Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects.

Effect of high-dose ibuprofen in patients with cystic fibrosis.

P304

1084-1089

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200702-181OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

176

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17872492

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

2176097

http://www.w3.org/2001/XMLSchema#string